Kristin C. Schuhwerk
Operationeel Directeur bij Scorpion Therapeutics, Inc.
Oorsprong van het eerstegraads netwerk van Kristin C. Schuhwerk
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA.
11
| Holding Company | Pharmaceuticals: Major | 11 |
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.
9
| Extinct | Pharmaceuticals: Major | 9 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Kristin C. Schuhwerk via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ARQULE, INC. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
| THE GOLDMAN SACHS GROUP, INC. | Investment Banks/Brokers | Corporate Officer/Principal | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Director/Board Member | |
| University of Notre Dame | College/University | Doctorate Degree | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member | |
| TRANSLATE BIO, INC. | Biotechnology | Founder Director/Board Member Corporate Officer/Principal | |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Oxford | College/University | Doctorate Degree Graduate Degree Undergraduate Degree | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
| FIBROGEN, INC. | Pharmaceuticals: Major | Director/Board Member | |
AlpInvest Partners BV
 AlpInvest Partners BV Investment ManagersFinance AlpInvest Partners BV (AlpInvest) is a private equity asset subsidiary AP BV, ultimately owned by The Carlyle Group, Inc founded in 2000. AlpInvest Partners BV is headquartered in Amsterdam, the Netherlands. | Investment Managers | Corporate Officer/Principal | |
| Stonehill College, Inc. | College/University | Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member | |
| ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Director/Board Member | |
| MEDIAN TECHNOLOGIES | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Telectronics Pacing Systems, Inc.
 Telectronics Pacing Systems, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Telectronics Pacing Systems, Inc. is a company that manufactures pacemakers. The company is based in Philadelphia, PA. | Medical Specialties | Corporate Officer/Principal | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal | |
Macrotarg Ltd.
 Macrotarg Ltd. BiotechnologyHealth Technology Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK. | Biotechnology | Director/Board Member | |
| ESSA PHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
| TREVI THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| The Johns Hopkins University School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
| JUNO THERAPEUTICS INC | Biotechnology | Director/Board Member | |
| CELLECTAR BIOSCIENCES, INC. | Pharmaceuticals: Major | Chairman Chief Tech/Sci/R&D Officer | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Biotechnology | Director/Board Member | |
| MORPHIC HOLDING, INC. | Pharmaceuticals: Major | Director/Board Member | |
Andrew Alliance SA
 Andrew Alliance SA Industrial MachineryProducer Manufacturing Andrew Alliance SA develops liquid handling solutions. Its product, Andrew, is a novel liquid handling robot designed for pipetting process. The firm's products include Andrew models, consumable dominos, protocol design, and enabling accessories. The company was founded by Piero Zucchelli, Giorgio Horak, and Antoine Jordan in March 2011 and is headquartered in Vernier, Switzerland. | Industrial Machinery | Director/Board Member | |
| IKENA ONCOLOGY, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| GOSSAMER BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Biotechnology | Director/Board Member | |
| KRONOS BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Novartis Inflammasome Research, Inc.
 Novartis Inflammasome Research, Inc. Pharmaceuticals: MajorHealth Technology Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Nuvation Bio Operating Co., Inc.
 Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
Adaptate Biotherapeutics Ltd.
 Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
| KINNATE BIOPHARMA INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Chief Executive Officer | |
| CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Ifm Therapeutics, Inc.
 Ifm Therapeutics, Inc. BiotechnologyHealth Technology Ifm Therapeutics, Inc. develops immunotherapy that focuses on targeting the adaptive immune system. The private company is based in Boston and was founded by Jean-Francois B. Formela. | Biotechnology | Founder Director/Board Member | |
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Director/Board Member | |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Miscellaneous Commercial Services | Chairman | |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Medical Specialties | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 37 |
| Verenigd Koninkrijk | 6 |
| Zwitserland | 3 |
| Frankrijk | 3 |
| Duitsland | 2 |
Sectoraal
| Health Technology | 30 |
| Finance | 7 |
| Consumer Services | 7 |
| Commercial Services | 7 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 180 |
| Corporate Officer/Principal | 42 |
| Chief Executive Officer | 36 |
| Independent Dir/Board Member | 35 |
| Chairman | 32 |
Sterkste connecties
| Insiders | |
|---|---|
| Jean-Francois Formela | 47 |
| Otello Stampacchia | 37 |
| Timothy Haines | 36 |
| Shelley Chu | 31 |
| James Manuso | 29 |
| Stephen Hill | 18 |
| Keith Flaherty | 16 |
| Arjun Goyal | 16 |
| Saurabh Saha | 16 |
| Michael J. Doyle | 16 |
| Oleg Nodelman | 15 |
| Axel Hoos | 10 |
| Guy Padbury | 8 |
| Joanne M. Protano | 7 |
| Adam Friedman | 6 |
- Beurs
- Insiders
- Kristin C. Schuhwerk
- Bedrijfsconnecties
